Product information and disease descriptionProduct descriptionProduct information
Product comparison
6 evidence topics · 6 sources
Network meta-analysis of phase 3 induction trials including obefazimod
“Thirty-three induction trials involving 17 therapies were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Upadacitinib demonstrated the highest relative efficacy for clinical remission (risk ratio, 6.90; 95% confidence interval, 3.54-12.45; P score, 0.95; high confidence) and endoscopic improvement (risk ratio, 5.29; 95% confidence interval, 3.38-8.28; P score, 0.97; moderate confidence).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In AT-naïve patients, obefazimod and upadacitinib showed the highest efficacy, whereas in AT-experienced patients, upadacitinib, ustekinumab, and tofacitinib ranked highest.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Novel therapies, like obefazimod and subcutaneous guselkumab, may represent highly effective alternatives.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote